Our Pipeline

Robust, focused, exciting in its potential.

Our pipeline centers on promising internally developed compounds.

Each was discovered by our own people. Each targets proven pathways to disrupting cancer growth. Each has potential for important patient impact.

Our Pipeline

Ponatinib*

Product: CML, Ph+ ALL (refractory)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: CML (2nd line)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: CML (dose-ranging)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Ph+ ALL (with chemo, 1st, 2nd line)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: AML (FLT3)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Lung cancer (FGFR, RET)
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Non-small cell lung cancer (ALK) - Resistant
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Non-small cell lung cancer (ALK) - 1st line
Phase: PreclinicalProof of ConceptPivotalApproved
Product: Non-small cell lung cancer (EGFR Exon 20, HER2 Exon 20)
Phase: PreclinicalProof of ConceptPivotalApproved

* Includes investigator-sponsored trials.